FDA 483 - ImprimisRx NJ - August 05, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
ImprimisRx NJ, a producer of sterile and non-sterile drug products, was cited for significant deficiencies in aseptic processing, environmental control, and cleaning practices during an FDA inspection. Observations included visibly dirty ISO 5 areas, inadequate personnel gowning and material disinfection, poor cleanroom maintenance, and issues with air quality and unidirectional airflow. The firm also released drug products with inconsistent potency due to variable capsule filling.
ID · e4cc7967-3ab1-43d0-913d-52bbaafb5198